Advertisement
Screener

TVARDI THERAPEUTICS, INC. (TVRD) Increase Decrease In Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

TVARDI THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability

TVARDI THERAPEUTICS, INC. (TVRD) reported Increase Decrease In Operating Lease Liability of -$56.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-14

  • TVARDI THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$28.00K.
  • TVARDI THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$28.00K.
  • TVARDI THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$28.00K.
  • TVARDI THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$26.00K.
  • TVARDI THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$103.00K.
  • TVARDI THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$93.00K.
  • TVARDI THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$1.92M.
  • TVARDI THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was -$1.75M.
Period endIncrease Decrease In Operating Lease Liability 3 monthIncrease Decrease In Operating Lease Liability 6 monthIncrease Decrease In Operating Lease Liability 9 monthIncrease Decrease In Operating Lease Liability 9 month as first filedIncrease Decrease In Operating Lease Liability 12 monthIncrease Decrease In Operating Lease Liability 12 month as first filed
2026-06-30-$28.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$56.00K
10-Q · filed 2026-08-14
-$84.00K
derived: sum of 3 quarters · filed 2026-08-14
-$110.00K
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$28.00K
10-Q · filed 2026-05-08
-$56.00K
derived: sum of 2 quarters · filed 2026-05-08
-$82.00K
derived: sum of 3 quarters · filed 2026-05-08
-$107.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$28.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$54.00K
derived: sum of 2 quarters · filed 2026-03-31
-$79.00K
derived: sum of 3 quarters · filed 2026-08-14
-$103.00K
10-K · filed 2026-03-31
2025-09-30-$26.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$51.00K
derived: sum of 2 quarters · filed 2026-08-14
-$75.00K
10-Q · filed 2025-11-13
-$99.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$25.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
-$49.00K
10-Q · filed 2026-08-14
-$73.00K
derived: sum of 3 quarters · filed 2026-08-14
-$97.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$24.00K
10-Q · filed 2026-05-08
-$48.00K
derived: sum of 2 quarters · filed 2026-05-08
-$72.00K
derived: sum of 3 quarters · filed 2026-05-08
2024-12-31-$24.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$48.00K
derived: sum of 2 quarters · filed 2026-03-31
-$93.00K
10-K · filed 2026-03-31
-$4.36M
10-K · filed 2025-03-11
2024-09-30-$24.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$69.00K
10-Q · filed 2025-11-13
-$4.36M
10-Q · filed 2024-11-14
2024-06-30-$45.00K
10-Q · filed 2025-08-14
2023-12-31-$640.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
-$982.00K
derived: sum of 2 quarters · filed 2025-03-11
-$1.46M
derived: sum of 3 quarters · filed 2025-03-11
-$1.92M
10-K · filed 2025-03-11
2023-09-30-$342.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
-$816.00K
derived: sum of 2 quarters · filed 2024-11-14
-$1.28M
10-Q · filed 2024-11-14
-$1.73M
derived: sum of 4 quarters · filed 2025-03-11
2023-06-30-$474.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
-$936.00K
10-Q · filed 2024-08-14
-$1.39M
derived: sum of 3 quarters · filed 2025-03-11
-$1.84M
derived: sum of 4 quarters · filed 2025-03-11
2023-03-31-$462.00K
10-Q · filed 2024-05-13
-$917.00K
derived: sum of 2 quarters · filed 2025-03-11
-$1.36M
derived: sum of 3 quarters · filed 2025-03-11
-$1.79M
derived: sum of 4 quarters · filed 2025-03-11
2022-12-31-$455.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
-$900.00K
derived: sum of 2 quarters · filed 2025-03-11
-$1.33M
derived: sum of 3 quarters · filed 2025-03-11
-$1.75M
10-K · filed 2025-03-11
2022-09-30-$445.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$877.00K
derived: sum of 2 quarters · filed 2023-11-13
-$1.30M
10-Q · filed 2023-11-13
-$1.72M
derived: sum of 4 quarters · filed 2024-03-06
2022-06-30-$432.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
-$855.00K
10-Q · filed 2023-08-07
-$1.27M
derived: sum of 3 quarters · filed 2024-03-06
-$1.68M
derived: sum of 4 quarters · filed 2024-03-06
2022-03-31-$423.00K
10-Q · filed 2023-05-15
-$839.00K
derived: sum of 2 quarters · filed 2024-03-06
-$1.25M
derived: sum of 3 quarters · filed 2024-03-06
-$1.64M
derived: sum of 4 quarters · filed 2024-03-06
2021-12-31-$416.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06
-$822.00K
derived: sum of 2 quarters · filed 2024-03-06
-$1.22M
derived: sum of 3 quarters · filed 2024-03-06
-$1.60M
10-K · filed 2024-03-06
2021-09-30-$406.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
-$800.00K
derived: sum of 2 quarters · filed 2022-11-07
-$1.19M
10-Q · filed 2022-11-07
2021-06-30-$394.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
-$780.00K
10-Q · filed 2022-08-08
2021-03-31-$386.00K
10-Q · filed 2022-05-09
2020-12-31-$1.09M
10-K · filed 2023-03-06
2019-12-31-$879.00K
10-K · filed 2022-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
MUSTANG BIO, INC. (MBIO)United States$0.013B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36